Recent developments include the company securing financing to support innovative growth initiatives and insider purchasing activity by the Chief Financial Officer.

• Lifeloc Technologies secured financing aimed at supporting innovative growth strategies as reported in March 2026 [N1].
• The Chief Financial Officer purchased 12,250 shares of the company's stock in April 2025, indicating insider confidence [N2].

Lifeloc's established fuel cell technology and patent portfolio provide a foundation for maintaining leadership in breath alcohol testing devices. The company's recent financing and merger activities indicate strategic efforts to expand and enhance its product offerings. Strong liquidity ratios suggest financial stability to support operations and growth. Insider buying activity may reflect confidence in the company's prospects. Continued innovation and successful commercialization of new products could strengthen its market position.

The company faces significant risks including customer concentration with no long-term contracts, reliance on a few key personnel, and exposure to supply chain disruptions from geopolitical and natural events. Its net losses and dependence on external financing highlight financial challenges. The stock's trading on illiquid OTC markets increases volatility and limits investor access. Competition from better-resourced firms and potential obsolescence of its technology pose ongoing threats. Regulatory compliance costs and potential patent litigation add operational risks.

Lifeloc's moat is based on its proprietary fuel cell technology for breath alcohol measurement, which has been developed and refined over many years. The company holds several important patents and invests in protecting its intellectual property. Its established relationships with key customers and suppliers, along with its specialized technology, provide some competitive advantage. However, the company faces competition from larger firms with greater resources and alternative technologies that could emerge. Customer concentration and reliance on key personnel also present challenges to sustaining its competitive position.

• Customer Concentration Risk: A significant portion of revenues comes from three customers without long-term contracts, posing a risk if these customers reduce or cease purchases.
• Key Personnel Dependence: The company relies heavily on its CEO and President; loss of this individual could severely impact business operations.
• Supply Chain and Geopolitical Risks: Dependence on global suppliers exposes the company to risks from natural disasters, political crises, trade policy changes, and international conflicts.
• Financial and Liquidity Risks: The company has incurred indebtedness requiring ongoing debt service, and its ability to meet obligations depends on generating sufficient cash from operations.
• Market and Stock Liquidity Risks: Common stock trades on OTC markets with low liquidity and high volatility, which may affect stock price stability and investor access.
• Regulatory and Compliance Costs: Compliance with evolving corporate governance, cybersecurity, and disclosure regulations increases expenses and diverts management attention.
• Technology and Competition Risks: Emerging technologies and competitors with greater resources may erode the company's market share and render its products obsolete.

• Lifeloc Technologies, Inc operates in the breath alcohol testing industry using fuel cell technology for measurement, which has been developed and refined over many years and is expected to remain dominant in their segment.
• The company relies on global third-party suppliers and service providers, which exposes it to risks from natural disasters, political crises, and other uncontrollable events that could disrupt operations or sales.
• Lifeloc is subject to data privacy and cybersecurity regulations; it stores information online and relies on third-party IT providers for cybersecurity risk management and incident response.
• The company faces risks from unstable market and economic conditions, including inflation, liquidity constraints, and geopolitical conflicts that may affect its supply chain and financial performance.
• Eighteen percent of 2025 product sales and sixteen percent of 2024 sales were attributable to three customers without long-term contracts, indicating customer concentration risk.
• The company depends heavily on its CEO and President, Dr. Wayne R. Willkomm, whose loss could severely damage the business.
• Lifeloc must attract and retain employees with scientific and technical skills amid intense competition for such talent.
• The company faces risks from changes in trade policy and tariffs that could increase costs and reduce demand internationally.
• Lifeloc has significant indebtedness including subordinated debentures and a mortgage, with debt service dependent on cash generation from operations.
• The principal stockholder, Vern D. Kornelsen, beneficially owned approximately 77% of outstanding common stock as of December 31, 2025, giving him significant control over corporate decisions.
• The company has never paid cash dividends and intends to retain earnings to support operations and expansion.
• Lifeloc issued options to employees and others, which may dilute existing shareholders.
• The company has a merger agreement with Electronic Systems Technology, Inc. to form a wholly owned subsidiary, subject to customary closing conditions.
• Financial snapshot for period ending December 31, 2025: revenue of $9.03 million, net loss of $2.47 million, basic and diluted EPS of -$0.9, current assets of $4.27 million, current liabilities of $0.84 million, cash and equivalents of $2.25 million, current ratio of 5.1, and cash ratio of 2.69.
• The company faces risks from product liability claims, environmental compliance, and potential patent infringement issues.
• Quarterly financial results may vary significantly due to timing of orders, R&D expenditures, production costs, regulatory changes, and customer demand.
• The company is subject to compliance costs related to corporate governance and public disclosure regulations, which divert management attention from revenue-generating activities.
• Lifeloc's common stock is not listed on a national exchange and trades on OTC markets, which are highly illiquid and subject to volatility.
• The company secured financing for growth initiatives as reported in March 2026.
• The Chief Financial Officer purchased 12,250 shares in April 2025, indicating insider buying activity.